AstraZeneca (AZN) Issues Encouraging Update on Durvalumab ATLANTIC Trial in NSCLC
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) provided an update on preliminary findings from the ATLANTIC trial of durvalumab as 3rd-line or later stage ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
